The GBA Multimodal Study in Parkinson's Disease

Multimodal Molecular Imaging and Biometric Analysis in GBA-PD and Asymptomatic GBA-mutation Carriers

Recruitment Information:

Seeking volunteers with following diagnosis: PD Study Type: Observational
Eligible Ages: 18 - 80 Status: Recruiting
Time Since Diagnosis: Any may be eligible Study Focus:

Study Purpose:

This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessment to study the typing patterns as possible biomarkers of early motor dysfunctions.

Find a Site Location and Contact the Trial Team

More Details

Study Rationale: People who have a mutation in the GBA gene have a higher risk of developing Parkinson's disease (PD) and, if they have PD, are more likely to have cognitive decline and dementia. Cognitive problems in people with PD is related to dysfunction of the brain chemical acetylcholine and likely to the accumulation of the tau protein in the brain. Another observation in previous studies is that analyzing the patterns of typing into a computer can help differentiate healthy people from people with PD. Hypothesis: The investigators hypothesize that people with GBA-related PD will have higher acetylcholine dysfunction and tau accumulation compared with non-GBA patients, and that these changes may start in the asymptomatic phase (i.e., people with the mutation but without symptoms of PD). The investigators also believe that the investigators will be able to detect subjects with higher degree of dopamine loss just by analyzing the way they type into a computer. Study Design: The investigators will recruit 25 subjects with a GBA mutation (10 subjects with PD and 15 asymptomatic carriers). All the participants will have a clinical evaluation and a typing session, and subsequently will undergo a brain MRI and three PET scans with a tau tracer, an acetylcholine tracer, and a dopaminergic tracer. A blood sample will also be taken for the analysis of GCase (the enzyme related to the GBA mutation). Impact on Diagnosis/Treatment of Parkinson's Disease: The results will help understand the changes that take place in the brain of people with GBA-related Parkinson's disease, and hopefully will shed light also on the pathophysiology of non-GBA-related Parkinson's, as well as on the molecular correlates of cognitive decline, especially in its early stage. The typing data along with dopaminergic imaging will clarify the possible role of using typing patterns to identify subjects with early stage Parkinson's disease. Next Steps for Development: The findings of this study may help identify biomarkers for cognitive decline in early Parkinson's disease, with a potential role in clinical trials. Also, if the hypothesis on the typing is confirmed, this approach may be studied in larger cohorts for early diagnosis of Parkinson's in other at-risk populations.

Phase: Lead Sponsor: Pacific Parkinson's Research Centre
Trial ID: 006483 Sponsor Type: Other
Primary Country: Canada Additional Collaborators or Sponsors: University of British Columbia, University of Washington, Oregon Health and Science University, Simon Fraser University, Michael J. Fox Foundation for Parkinson's Research, Silverstein Foundation, Weston Brain Institute
Estimated Enrollment: 25 Study Start Date: May 2019
Estimated Study Completion Date: April 2021 Source: ClinicalTrials.gov
Study Website:

More Inclusion & Exclusion Criteria

Share This Trial


Fox Trial Finder strives to make all trial postings as accurate and complete as possible. If you believe any of the information on this page is not accurate, click here to contact us. Thank you for your support.

Choose your location

Please select a Trial Location.
x

Confirmation

You have favorited this trial!

This trial will be listed in the "Favorites" category of your dashboard.
x

Confirmation

You are not interested.

This trial will be listed in the "Not Interested" category on your dashboard. You can click "Interested" if you change your mind.
x

Message to Trial Coordinator

Your message was sent.

Your message was sent to the trial team at the location you selected. Check your dashboard for a response.

Login to Fox Trial Finder

Please enter your email address and password to access your My Fox Trial Finder dashboard.



*indicates required field.
x

Contact Fox Trial Finder

What best describes you?





*indicates required field.
x